アミロイドーシス治療市場規模、シェア、成長分析：タイプ別、最終用途別、地域別 - 産業予測 2025～2032年

アミロイドーシス治療市場規模は2023年に58億7,000万米ドルと評価され、2024年の63億2,000万米ドルから2032年には113億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.6％で成長する見通しです。

世界のアミロイドーシス治療市場は、高齢化が進む中、認知度の向上、診断率の改善、治療オプションの進歩に後押しされ、顕著な成長を遂げています。臓器機能障害を引き起こすアミロイド蛋白の蓄積によって特徴づけられるアミロイドーシスは、化学療法、幹細胞移植、モノクローナル抗体や低分子阻害剤のような最先端の標的治療などの治療における技術革新を推進し、注目を集めています。これらの新しいアプローチは、病気の進行を止めたり逆転させたりする可能性を示しており、製薬会社の研究開発への大きな投資を促しています。治療費の高騰や、患者の予後を改善するための早期診断の重要性といった課題にもかかわらず、効果的な治療法が続々と登場していることから、アミロイドーシス治療市場は今後も成長軌道を維持するものと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

アミロイドーシス治療市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 治療法
  • 化学療法
  • 標的療法
  • 抗血管新生療法
  • モノクローナル抗体
  • プロテアソーム阻害剤
• 手術
  • 骨髄移植/幹細胞移植
  • 臓器移植

アミロイドーシス治療市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 病院・クリニック
• 外来手術センター
• 在宅ケア
• その他

アミロイドーシス治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Alnylam Pharmaceuticals（United States）
• Ionis Pharmaceuticals（United States）
• Intellia Therapeutics（United States）
• Genmab（Denmark）
• Pfizer（United States）
• BridgeBio Pharma（United States）
• Eidos Therapeutics（United States）
• Prothena Corporation（United States）
• Alexion Pharmaceuticals（United States）
• SOM Biotech（Spain）
• Neurimmune（Switzerland）
• Corino Therapeutics（United States）
• Proclara Biosciences（United States）
• Arcturus Therapeutics（United States）
• Dicerna Pharmaceuticals（United States）
• GlaxoSmithKline（United Kingdom）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）

結論と提言

Amyloidosis Treatment Market size was valued at USD 5.87 billion in 2023 and is poised to grow from USD 6.32 billion in 2024 to USD 11.35 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The global amyloidosis treatment market is experiencing notable growth, fueled by rising awareness, improved diagnostic rates, and advancements in therapeutic options amid an aging population. Characterized by the buildup of amyloid proteins causing organ dysfunction, amyloidosis has garnered increased attention, driving innovations in treatment, such as chemotherapy, stem cell transplantation, and cutting-edge targeted therapies like monoclonal antibodies and small molecule inhibitors. These novel approaches are demonstrating potential in halting or reversing disease progression, prompting significant investments in R&D from pharmaceutical companies. Despite challenges like high treatment costs and the critical need for early diagnosis to enhance patient outcomes, the continued emergence of effective therapies suggests that the amyloidosis treatment market will sustain its growth trajectory in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Amyloidosis Treatment Market Segments Analysis

Global Amyloidosis Treatment Market is segmented by Type, End-use and region. Based on Type, the market is segmented into Medication and Surgery. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Amyloidosis Treatment Market

The rising incidence of amyloidosis, encompassing both AL amyloidosis and ATTR amyloidosis, serves as a crucial driver for the market. Enhanced awareness and advancements in diagnostic techniques are contributing to an increase in accurate diagnoses, resulting in a larger population of patients who require effective treatment options. As more individuals are identified and confirmed as having this condition, the demand for innovative therapies and comprehensive care is expected to grow significantly, thereby propelling the amyloidosis treatment market forward. This upward trend in patient identification highlights the urgency for improved treatment solutions and fosters ongoing research and development in this field.

Restraints in the Amyloidosis Treatment Market

The amyloidosis treatment market faces significant challenges due to the limited availability of effective treatment options, despite ongoing advancements in research and drug development. Many individuals diagnosed with amyloidosis experience inadequate responses to existing therapies, highlighting the urgent need for more effective solutions. This situation not only hampers patient outcomes but also creates a pressing demand for innovative treatments that can address the unique complexities of the disease. As a result, the market is restrained by the necessity for enhanced therapeutic options that can better meet the needs of patients struggling with this challenging condition.

Market Trends of the Amyloidosis Treatment Market

The amyloidosis treatment market is witnessing a significant shift towards advancements in targeted therapies, driven by intensive research and development. Pharmaceutical companies are increasingly focusing on monoclonal antibodies and small molecules, which aim to inhibit the production and deposition of amyloid proteins characteristic of the disease. This innovative approach seeks to enhance patient outcomes by directly addressing the underlying pathophysiology. Ongoing clinical trials are crucial in evaluating the safety and efficacy of these novel treatments, indicating a promising future for therapeutic options. As these therapies progress towards approval, they are expected to fundamentally redefine the treatment landscape for amyloidosis, creating lucrative opportunities within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Amyloidosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Medication
  • Chemotherapy
  • Targeted therapy
  • Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
• Surgery
  • Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation

Global Amyloidosis Treatment Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Treatment Market Size & CAGR (2025-2032)

• North America (Type, End-use)
  • US
  • Canada
• Europe (Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Alnylam Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proclara Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcturus Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dicerna Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations